摘要
树突状细胞是目前已知功能最强的抗原提呈细胞,在启动细胞免疫中起关键作用。本文介绍以树突状细胞为基础的肿瘤免疫治疗,尤其在乳腺癌中应用的概况。
出处
《国际外科学杂志》
2006年第3期219-223,共5页
International Journal of Surgery
参考文献25
-
1Holger H, Angus W. Dendritic cells: emerging pharmacological targets of immunosuppressive drugs. Nature, 2000, 24 (4):24-33.
-
2Bell D, Chomarat P, Broyies D, et al. In breast carcinoma tissue,immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J Exp Med, 1999,190(10):1417-1426.
-
3Tsuge T, Yamakaw M, Tsukamoto M. Infiltrating dendritic/langerhans cells in primary breast cancer. Breast Cancer Res Treat,2000, 59(2): 141-152.
-
4Hsu FJ, Benike C, Fagnoni F, et al, Vaccination of patients with B-cell lymphoma using autilogous antigen-pulsed dendritic cells. Nat Med, 1996, 2: 52-58.
-
5Lyerly HK. A phase Ⅰ study of active immuno-therapy with carcinoembryonic antigen RNA-pulsed autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen human. Gene Ther, 1998, 9: 394-399.
-
6Murphy G, Tioa B, Ragde H, et al. Phase Ⅰ clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A020l-speeifie peptides-from prostate-specific membrane antigen. Prostate, 1996, 29: 371-380.
-
7Cranmer LD, Trevor KT, Hersh EM. Clinical applications of dendritic cell vaccination in the treatment of cancer. Cancer Immunol immunother, 2004, 53:275-306.
-
8Hart I, Colaco C. Fusion induces tumor rejection. Nature, 1997,388(8) : 626-627.
-
9Gong J, Avigan D, Chen D,et al. Activation of anti-tumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells. Proc Nail Acad Sci USA, 2000, 97 ( 6 ) : 2715-2718.
-
10Fields RC, Shimizu K, Mule JJ. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci USA, 1998, 95 (16) : 9482-9487.
同被引文献49
-
1赵海峰,孔瑞,孙备,王凤军.免疫调节在外科感染中的应用进展[J].国际外科学杂志,2006,33(5):386-389. 被引量：4
-
2Trikha M, Yan L, Nakada MT. Monoclonal antibodies as therapeutics in oncology [ J ]. Curr Opin Biotechnol, 2002,13 (6) :609-614.
-
3Cragg MS, Glennie MJ. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents [ J ]. Blood, 2004 , 103 (7): 2738-2743.
-
4Johnson P , Glennie M, The mechanisms of action of rituximab in the elimination of tumor cells[J]. Semin Oncol, 2003 ,30( 1 Suppl 2) :3-8.
-
5Cheung NK, Modak S, Vickers A, et al. Orally administered betaglucans enhance anti-tumor effects of monoclonal antibodies [ J ]. Cancer Immunol Immunother , 2002,51 (10) :557-564.
-
6Loberg RD, Wojno KJ, Day LL, et al. Analysis of membrane-bound complement regulatory proteins in prostate cancer[J]. Urology,2005 ,66(6) :1321-1326.
-
7Gelderman KA, Kuppen PJ, Bruin W, et al. Enhancement of the complement activating capacity of 17-1A mAb to overcome the effect of membrane-bound complement regulatory proteins on colorectal carcinoma[ J]. Eur J Immunol,2002 ,32( 1 ) :128-135.
-
8McDowell JV, Tran E, Hamilton D, et al. Analysis of the ability of spirochete species associated with relapsing fever, avian borreliosis, and epizootic bovine abortion to bind factor H and cleave c3b[J]. J Clin Microbiol, 2003 ,41(8) :3905-3910.
-
9Macor P, Mezzanzanica D, Cossetti C, et al. Complement activated by chimeric anti-folate receptor antibodies is an efficient effector system to control ovarian carcinoma [ J ]. Cancer Res, 2006,66 ( 7 ) : 3876-3883.
-
10Ziller F, Macor P, Bulla R, et al. Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59 [ J ]. Immunol,2005,35 (7) :2175-2183.
二级引证文献2
-
1林治华,万瑾,谢伟.补体系统与肿瘤免疫[J].重庆理工大学学报（自然科学）,2010,24(5):33-36. 被引量：9
-
2汤中敏,涂强,陆怡文,沈柳恒,余良,汤爱群.脉搏波传导速度危险因素相关性及创伤感染分析[J].中华医院感染学杂志,2011,21(5):911-912.
-
1郝俊芳,王裕葵.我国食管癌放射治疗的概况[J].中级医刊,1994,29(3):40-41. 被引量：1
-
2李筱梅.中医药治疗急性白血病概况[J].中西医结合杂志,1989,9(6):378-379.
-
3刘雅勤,孙雨时.国内伽玛刀治疗脑肿瘤概况[J].中风与神经疾病杂志,1999,16(2):127-128.
-
4朱传升.淋巴瘤的误诊概况与治疗进展[J].临床误诊误治,2000,13(3):179-181. 被引量：16
-
5张文范.日本胃癌研究进展的概况[J].实用肿瘤学杂志,1990,4(2):76-82.
-
6李莉,苏杏满,程建新.卵巢肿瘤标记物概况[J].河北医科大学学报,1998,19(2):123-124.
-
7张慧芹,刘阁玲.基质金属蛋白酶-9在甲状腺癌中的表达及临床意义[J].医学理论与实践,2005,18(4):389-390. 被引量：14
-
8曹雪涛.抗原提呈细胞与肿瘤生物治疗[J].中国肿瘤生物治疗杂志,1997,4(3):170-171. 被引量：7
-
9汤美雯.树突状细胞与肿瘤免疫治疗[J].亚太传统医药,2012,8(10):211-212. 被引量：1
-
10曹雪涛.树突状细胞与肝癌的免疫治疗[J].中华肝脏病杂志,2003,11(3):133-134. 被引量：21
